- Home
- EOD vs CUE Comparison
EOD vs CUE Comparison
Compare EOD & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOD | CUE |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.0M | 233.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | EOD | CUE |
|---|---|---|
| Price | $6.33 | $25.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | 118.8K | ★ 402.3K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $5.51 | $0.17 |
| 52 Week High | $6.74 | $45.50 |
Technical Indicators
Market Signals| Indicator | EOD | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 42.64 |
| Support Level | $6.30 | $23.51 |
| Resistance Level | $6.45 | $33.11 |
| Average True Range (ATR) | 0.08 | 4.91 |
| MACD | -0.00 | -0.83 |
| Stochastic Oscillator | 54.17 | 11.41 |
Price Performance
Historical ComparisonAbout EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.